The Impact of Pelvic Lymphadenectomy on the Survival of Patients Who Underwent Radical Cystectomy for Transitional Cell Carcinoma of the Bladder.
- Author:
Hwang Gyun JEON
1
;
Ja Hyeon KU
;
Hyeon JEONG
;
Cheol KWAK
;
Eunsik LEE
;
Chongwook LEE
;
Sang Eun LEE
Author Information
1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Bladder;
Bladder tumor;
Cystectomy
- MeSH:
Carcinoma, Transitional Cell*;
Cystectomy*;
Humans;
Lymph Node Excision*;
Lymphatic Diseases;
Multivariate Analysis;
Neoplasm Metastasis;
Prognosis;
Retrospective Studies;
Survival Rate;
Urinary Bladder Neoplasms;
Urinary Bladder*
- From:Korean Journal of Urology
2004;45(2):103-107
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We assessed the impact of pelvic lymphadenectomy on the survival of patients who had undergone radical cystectomy. MATERIALS AND METHODS: We retrospectively reviewed 107 patients who underwent radical cystectomy for transitional cell carcinoma of the bladder between January 1991 and December 2000. We preoperatively excluded patients with evidence of pelvic lymphadenopathy and distant metastases from the study. Among 107 patients, 61 patients (Group A) underwent pelvic lymphadenectomy while 46 patients (Group B) did not. The clinicopathological parameters were not significantly different in the two groups. RESULTS: In group A, 12 patients (19.6%) were found to have pelvic node metastases. Five-year overall survival and recurrence-free survival rates were 68% and 75% for Group A, respectively. In group B, 5-year overall survival and recurrence-free survival rates were 36% and 56%, respectively. Multivariate analysis revealed that T stage (p=0.004) and lymphadenectomy (p=0.044) were significant prognostic factors for survival. CONCLUSIONS: The overall survival rates between the two groups were significantly different. Our findings suggested that lymphadenectomy may improve the prognosis of patients who underwent radical cystectomy for transitional cell carcinoma of the bladder.
